Natural History Study for Patients with Angelman Syndrome

Launched by CENTRE HOSPITALIER UNIVERSITAIRE DE LIEGE · Jan 17, 2024

Keywords

ClinConnect Summary

This clinical trial is studying Angelman Syndrome, a genetic condition that affects the development and functioning of the brain. The trial will take place over four years in Belgium and aims to gather information about how this condition progresses in patients. Researchers plan to include 10 participants, who will be followed for two years after an initial recruitment period. They will use various assessments and questionnaires to collect data on the patients' motor skills and overall development.

To be eligible for this study, participants must have a confirmed genetic diagnosis of Angelman Syndrome and be between the ages of 0 and 99. Both males and females can take part, but their caregivers must agree to help them participate. It's important to note that individuals with other health conditions that might interfere with the study results will not be included. Participants can expect regular check-ins every six months during the two-year follow-up period, helping researchers better understand the natural history of Angelman Syndrome.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Genetically confirmed diagnosis of AS
• • 0-99 years
• • Male or Female
• • Participant's carer is willing to give IC/sign a "record of consultation" for participation in the study
• Exclusion Criteria:
• • comorbidity that could potentially affect the results of the study coexists. This